GNMLF (Genomma Lab InternacionalB de CV) EV-to-EBIT : 6.95 (As of May. 04, 2025)

View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genomma Lab InternacionalB de CV's Enterprise Value is $1,404.7 Mil. Genomma Lab InternacionalB de CV's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $202.1 Mil. Therefore, Genomma Lab InternacionalB de CV's EV-to-EBIT for today is 6.95.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's EV-to-EBIT or its related term are showing as below:

GNMLF' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.61 Med: 8.39 Max: 18.02
Current: 6.92

During the past 13 years, the highest EV-to-EBIT of Genomma Lab InternacionalB de CV was 18.02. The lowest was -30.61. And the median was 8.39.

GNMLF's EV-to-EBIT is ranked better than
84.9% of 682 companies
in the Drug Manufacturers industry
Industry Median: 16.345 vs GNMLF: 6.92

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genomma Lab InternacionalB de CV's Enterprise Value for the quarter that ended in Mar. 2025 was $1,627.2 Mil. Genomma Lab InternacionalB de CV's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $202.1 Mil. Genomma Lab InternacionalB de CV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 12.42%.

Genomma Lab InternacionalB de CV EV-to-EBIT Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV EV-to-EBIT Chart

Genomma Lab InternacionalB de CV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-EBIT

Get a 7-Day Free Trial

8.97

9.86

7.69

7.05

7.66

Genomma Lab InternacionalB de CV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															7.40	7.24	7.79	7.66	7.40

Competitive Comparison of Genomma Lab InternacionalB de CV's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genomma Lab InternacionalB de CV's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Genomma Lab InternacionalB de CV EV-to-EBIT Calculation

Genomma Lab InternacionalB de CV's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1404.650	/	202.09
	=	6.95

Genomma Lab InternacionalB de CV's current Enterprise Value is $1,404.7 Mil.
Genomma Lab InternacionalB de CV's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $202.1 Mil.

Genomma Lab InternacionalB de CV (OTCPK:GNMLF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genomma Lab InternacionalB de CV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 )	=	EBIT	/	Enterprise Value (Q: Mar. 2025 )
	=	202.09	/	1627.16299
	=	12.42 %

Genomma Lab InternacionalB de CV's Enterprise Value for the quarter that ended in Mar. 2025 was $1,627.2 Mil.
Genomma Lab InternacionalB de CV's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $202.1 Mil.

Genomma Lab InternacionalB de CV EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomma Lab InternacionalB de CV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

LABB:Mexico GEKA:Germany

Address

Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210

Website

https://www.genommalab.com

Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.